Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
July 30, 2015
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
In drug discovery, generating targets is no longer the challenge. The real question is how to identify the few worth investing months of research and significant resources to pursue. Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
July 7, 2026
Stay up to date with the latest company updates, milestones, and announcements.
Explore upcoming conferences and scientific meetings where you can connect with our team.
At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.
Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.
Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.
Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.
Dr. Rachel Johnson – Lead Scientist
Dr. Rachel Johnson is a Lead Scientist at Sygnature Discovery. Within the Protein Science and Structure department, she is part of the membrane protein team and specializes in the purification and cryo-EM structure determination of GPCRs.
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
